ASCO 2025 News: Lifileucel Produces Long-Term Responses and Survival in Advanced Melanoma
One-time treatment with lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) continues to show deep, durable responses and meaningful survival in patients with advanced melanoma, according to a five-year analysis of the C-144-01 trial.